

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season**

as of February 14, 2020, June 30, 2020

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	1 <sup>a</sup> (0.2%)	17 <sup>b</sup> (1.5%)	17 <sup>b</sup> (1.5%)	0	0	10 (100%)	0	0	0	0	0	5 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	408	1,119	1,119	201	201	10	32	26	26	26	26	5	9	18	18	18	18
<b>Number of viruses reported</b>	3,046						89						117				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 1

<sup>b</sup> Patients without treatment 12